AKT1 and neoplasm: In a study of hepatocellular carcinoma, MAP17 was described as a hypoxia-induced glycolytic regulator in the tumor microenvironment, coupling aerobic glycolysis to tumor growth via the activation of the ROS/AKT pathway and HIF1α [54].